NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON), Royal Caribbean Group (NYSE: RCL), Mesoblast Limited (NASDAQ: MESO), and Loop Industries, Inc. (NASDAQ: LOOP). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link

Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON)

Class Period: May 10, 2017 to September 25, 2020

Lead Plaintiff Deadline: December 4, 2020

On September 25, 2020, the U.S. Securities and Exchange Commission (SEC) issued a cease and desist order against Precigen. The cease and desist order involved inaccurate reports concerning the companys purported success converting relatively inexpensive natural gas into more expensive industrial chemicals using a proprietary methane bioconversion (MBC) program. The order noted that the Company was primarily using significantly more expensive pure methane for the relevant laboratory experiments but was indicating that the results had been achieved using natural gas. The cease-and-desist order further stated that although the Company pitched the MBC program privately to numerous potential business partners over the course of 2017 and 2018 and [a] number of these potential partners performed due diligence on the MBC program including reviewing lab results and plans for commercialization. [The Company] has not yet found a partner for the MBC program.

The complaint, filed on October 5, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose to investors that: (1) the Company was using pure methane as feedstock for its announced yields for its methanotroph bioconversion platform instead of natural gas; (2) yields from natural gas as a feedstock were substantially lower than the aforementioned pure methane yields; (3) due to the substantial price difference between pure methane and natural gas, pure methane was not a commercially viable feedstock; (4) the Companys financial statements for the quarter ended March 31, 2018 were false and could not be relied upon; (5) the Company had material weaknesses in its internal controls over financial reporting; (6) the Company was under investigation by the SEC since October 2018; and (7) as a result of the foregoing, defendants public statements were materially false and misleading at all relevant times.

For more information on the Precigen class action go to: https://bespc.com/cases/PGEN

Royal Caribbean Group (NYSE: RCL)

Class Period: February 4, 2020 to March 17, 2020

Lead Plaintiff Deadline: December 7, 2020

The complaint, filed on October 7, 2020, alleges that throughout the Class Period defendants failed to disclose material facts about the Companys decrease in bookings outside China, instead maintaining that it was only experiencing a slowdown in bookings from China. The Action further alleges that defendants failed to disclose material facts about the Companys inadequate policies and procedures to prevent the spread of COVID-19 on its ships. The truth about the scope of the impact that COVID-19 had on the Companys overall bookings and the inability of Royal Caribbean to prevent the virus spread on its ships was revealed through a series of disclosures.

First, on February 13, 2020, Royal Caribbean issued a press release stating that it had canceled 18 voyages in Southeast Asia due to recent travel restrictions and further warning that recent bookings had been softer for its broader business.

On this news, Royal Caribbean shares fell over 3 percent.

Second, on February 25, 2020, Royal Caribbean filed its 2019 Form 10-K, indicating that COVID-19 concerns were negatively impacting its overall business.

On this news, Royal Caribbean shares fell over 14 percent.

Third, on March 10, 2020, Royal Caribbean withdrew its 2020 financial guidance, increased its revolving credit facility by $550 million, and announced that it would take cost-cutting actions due to the proliferation of COVID-19, further revealing that COVID-19 was severely impacting Royal Caribbeans 2020 customer booking and that its safety measures were inadequate to prevent the spread of the virus on its ships.

On this news, Royal Caribbean shares fell over 14 percent.

Fourth, on March 11, 2020, Royal Caribbeans largest competitor, Carnival, announced a 60-day suspension of all operations, prompting concern that Royal Caribbean would follow suit. At the same time, Royal Caribbean also cancelled two cruises, beginning a series of cancellations and suspensions to follow.

On this news, Royal Caribbean shares fell almost 32 percent.

Fifth, on March 14, 2020, Royal Caribbean announced a suspension of all global cruises for 30 days.

On this news, Royal Caribbean stock fell over 7 percent.

Sixth, on March 16, 2020, the Company revealed that global operations could be suspended longer than anticipated, announcing the cancellations of two additional cruises throughout April and into May.

On this news, Royal Caribbean shares fell over 7 percent.

Finally, on March 18, 2020, analysts downgraded Royal Caribbeans stock and slashed their price targets.

On this news, Royal Caribbean shares fell more than 19 percent.

For more information on the Royal Caribbean class action go to: https://bespc.com/cases/RCL

Mesoblast Limited (NASDAQ: MESO)

Class Period: April 16, 2019 to October 1, 2020

Lead Plaintiff Deadline: December 7, 2020

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial to treat children with steroid refractory acute graft versus host disease (aGVHD).

In early 2020, Mesoblast completed its rolling submission of its Biologics License Application (BLA) with the FDA to secure marketing authorization to commercialize remestemcel-L for children with steroid refractory aGVHD.

On August 11, 2020, the FDA released briefing materials for its Oncologic Drugs Advisory Committee (ODAC) meeting to be held on August 13, 2020. Therein, the FDA stated that Mesoblast provided post hoc analyses of other studies to further establish the appropriateness of 45% as the null Day-28 ORR for its primary endpoint. The briefing materials stated that, due to design differences between these historical studies and Mesoblasts submitted study, it is unclear that these study results are relevant to the proposed indication.

On this news, the Companys share price fell $6.09, or approximately 35%, to close at $11.33 per share on August 11, 2020.

On October 1, 2020, Mesoblast disclosed that it had received a Complete Response Letter (CRL) from the FDA regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that the Company conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD. The CRL also identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the products biologic activity.

On this news, the Companys share price fell $6.56, or 35%, to close at $12.03 per share on October 2, 2020.

The complaint, filed on October 8, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that comparative analyses between Mesoblasts Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD due to design differences between the four studies; (2) that, as a result, the FDA was reasonably likely to require further clinical studies; (3) that, as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) that, as a result of the foregoing, defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Mesoblast class action go to: https://bespc.com/cases/MESO

Loop Industries, Inc. (NASDAQ: LOOP)

Class Period: September 24, 2018 to October 12, 2020

Lead Plaintiff Deadline: December 14, 2020

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that Loops scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the companys process internally. The report also stated that Loops previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were technically and industrially impossible, according to a former employee. Moreover, the report alleged that Executives from a division of key partner Thyssenkrupp, who Loop entered into a global alliance agreement with in December 2018, told us their partnership is on indefinite hold and that Loop underestimated both costs and complexities of its process.

On this news, the Companys share price fell $3.78, or over 32%, to close at $7.83 per share on October 13, 2020.

The complaint, filed on October 13, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that Loop scientists were encouraged to misrepresent the results of Loops purportedly proprietary process; (2) that Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) that, as a result, the Company was unlikely to realize the purported benefits of Loops announced partnerships with Indorama and Thyssenkrupp; and (4) that, as a result of the foregoing, defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Loop class action go to: https://bespc.com/cases/Loop

About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit http://www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Melissa Fortunato, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Go here to see the original:
Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, Mesoblast, and Loop...

Bone Marrow Stem Cells Comments Off on Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, Mesoblast, and Loop… | November 5th, 2020

The success of approved stem cell therapies has caused a surge in interest of biopharma developers in this field; many innovator companies are currently progressing proprietary leads across different phases of clinical development, with cautious optimism

Roots Analysis has announced the addition of Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)) report to its list of offerings.

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years.

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

Key Market Insights

Over 280 stem cell therapies are under development, most of which are allogeneic productsMore than 50% of the pipeline candidates are in the mid to late phase trials (phase II and above), and allogenic therapies (majority of which are derived from the bone marrow) make up 65% of the pipeline.

70% of pipeline candidates are based on mesenchymal stem cellsIt is worth highlighting that the abovementioned therapies are designed to treat musculoskeletal (22%), neurological (21%) and cardiovascular (15%) disorders. On the other hand, hematopoietic stem cell-based products are mostly being evaluated for the treatment of oncological disorders, primarily hematological malignancies.

Close to 85% stem cell therapy developers are based in North America and Asia-Pacific regionsWithin these regions, the US, China, South Korea and Japan, have emerged as key R&D hubs for stem cell therapies. It is worth noting that majority of the initiatives in this domain are driven by small / mid-sized companies

Over 1,500 grants were awarded for stem cell research, since 2015More than 45% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NICHD, NIDDK, NIGMS and OD emerged as key organizations that have offered financial support for time periods exceeding 25 years as well.

Outsourcing has become indispensable to R&D and manufacturing activity in this domainPresently, more than 80 industry / non-industry players, based in different regions across the globe, claim to provide contract development and manufacturing services to cater to the unmet needs of therapy developers. Examples include (in alphabetical order) Bio Elpida, Cell and Gene Therapy Catapult, Cell Tech Pharmed, GenCure, KBI Biopharma, Lonza, MEDINET, Nikon CeLL innovation, Roslin Cell Therapies, WuXi Advanced Therapies and YposKesi.

North America and Asia-Pacific markets are anticipated to capture over 80% share by 2030The stem cell therapies market is anticipated to witness an annualized growth rate of over 30% during the next decade. Interestingly, the market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom stem cell therapies are currently considered to be a promising alternatives for the treatment of a myriad of disease indications, with the potential to overcome challenges associated with conventional treatment options. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), stem cell therapy portfolio and an informed future outlook.

For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html

or email [emailprotected]

You may also be interested in the following titles:

Contact:

Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]

See original here:
Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader

Cardiac Stem Cells Comments Off on Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 – PRnews Leader | November 5th, 2020

With all the attention still focused on the devastating COVID-19 pandemic despite Australia slowly moving towards a new normal heart disease remains the countrys leading cause of death. It kills one person every 12 minutes, and causes one in four deaths in Australia and beyond.

The heart beats without our active thought, which is why, perhaps, we take for granted the health of this rhythmic, ticking pump; our most vital organ.

Watchthe 'A Different Lens' live event viaFacebookorLinkedInat 7.30pm on Thursday, 5 November

With the launch now of Monash Universitys Victorian Heart Institute (VHI), and the Victorian Heart Hospital (VHH) also opening on campus in 2022, the focus from the experts involved will be on this one-organ system, although from an expansive range of medical and other disciplines. When the under-construction hospital opens, the two new heart hubs will be housed in the same building, making it the centre of heart research, teaching and cardiac care in Australia. It will be the first and only dedicated heart hospital in the country.

Every year, 50,000 Australians will suffer a heart attack, killing 20 people a day, with one person dying every 12 minutes.

Professor Steve Nicholls, a world-renowned cardiologist originally from Adelaide, heads both. The work of the new institute is already underway, and is expected to break down barriers between research, teaching and clinical care.

There is something incredibly exciting about the fact that biomedical research will be happening in the same building that we will treat patients, Professor Nicholls says.

He's outlined what he calls the "five grand challenges"for the next decade of heart research, with the ambition of shifting the status quo in heart disease.

They are:

Living well is understanding that we need to take a more holistic approach to treating heart health, Professor Nicholls says.

We need to consider diet, sleep, mindfulness and wellbeing, but also survivorship. People who survive other diseases like cancer now find themselves at a great risk of heart disease. How do we improve health, and the patient experience for them?

Dr Emily Kotschet, a Monash cardiologist and electrophysiologist, is a specialist in the technology and "mechanical intervention"(pacemaker) side of the equation.

Technology is best when you are advancing in terms of treatment, not just prevention, she says.

The advances right now are miniaturisation and digital technology for managing patients remotely implantables that are remote-accessed, self-sufficient and patient driven. With the patients in more control than ever, their experience is continually improving.

Technologically, the old pacemaker was a big can on your shoulder with leads to the heart, she says.

The new ones are like AAA batteries that sit beside the heart. As we miniaturise for treatment, there will be way more engagement with patients to pick up their symptoms early and get on top of them early. Discussions with IT academics at Monash will bridge the gap between our method and the digital platforms that are emerging.

Dr Kotschet also says womens heart health has not had the media profile and reach that breast cancer has, so public awareness is low.

I think breast cancer really got cancer into the spotlight 15 or 20 years ago with celebrities and endorsements, and they are now well-funded. Their [clinical]trials are travelling quite nicely. Now I think its time for heart disease as a big killer to find its spotlight.

This ability to more freely collaborate across university disciplines on an ostensibly "medical"issue is a priority for the heart specialists and clinicians.

The head of the School of Public Health and Preventive Medicine, Professor Sophia Zoungas, is a leading expert in screening and managing cardiovascular disease. She likens the new institute and hospital to a forward-thinking company such as Google that, when presented with a problem, draws in the best minds available to help solve it.

Despite the fact the institute and hospital have a physical location, it also provides a forum for virtual, broader work, bringing in areas across the University that may not be co-located, she says.

Whether thats public health, engineering, science hopefully it will also provide that core clinical training for clinicians and researchers in the one place. We will be able to track the best people, the best minds.

She says COVID-19 has put heart disease further under the radar.

People forget heart disease is still our biggest killer. We have all been a little distracted this year with the global pandemic but even within the context of this pandemic, one of the most serious outcomes of it [for patients]has been the cardiovascular complications.

For Professor Peter Currie, the head of Monashs renowned Australian Regenerative Medicine Institute (ARMI), the future of heart health relies on scientists understanding the fundamental building blocks of the heart. Despite the heart being unable to repair itself (unlike other organs), and the fact that stem cells do not work, Professor Currie has an optimistic view of how regenerative medicine can create the heart disease solutions of the future. He sees this is as the challenge, and the new institute and hospital as the place to do it.

I think the great opportunity is to cherry-pick interested and dedicated researchers who have an interest in this area of biology and medicine to work on these big problems.

Everyone thinks cardiovascular disease has been hit on the head because weve got a few drugs, he says, but nothing could be further from the truth.

Originally posted here:
ADL live: Matters of the Heart Monash University - Monash Lens

Cardiac Stem Cells Comments Off on ADL live: Matters of the Heart Monash University – Monash Lens | November 5th, 2020

-   New Drug Application (NDA) for trilaciclib in small cell lung cancer accepted for Priority Review with a PDUFA action date of February 15, 2021-   Announced CEO succession plan in evolution to commercial-stage company-   Management to host webcast and conference call today at 4:30 p.m. ET

Originally posted here:
G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update

Global News Feed Comments Off on G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update | November 5th, 2020

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended September 30, 2020.

Continue reading here:
PRA Health Sciences, Inc. Reports Third Quarter 2020 Results and Updates Full Year 2020 Guidance

Global News Feed Comments Off on PRA Health Sciences, Inc. Reports Third Quarter 2020 Results and Updates Full Year 2020 Guidance | November 5th, 2020

DEER PARK, Ill., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report third quarter 2020 financial and operating results on Thursday, November 12, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).

Follow this link:
Eton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020

Global News Feed Comments Off on Eton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020 | November 5th, 2020

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.

See the original post here:
Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Global News Feed Comments Off on Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update | November 5th, 2020

NEW YORK and CUPERTINO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Narayan Prabhu will join the combined public company as Chief Financial Officer following the completion of Tenzing’s proposed business combination with Reviva (the “Business Combination”). Mr. Prabhu will report directly to Reviva’s Founder, President, and Chief Executive Officer Laxminarayan Bhat, Ph.D. Mr. Prabhu will join the combined public company, following the completion of the Business Combination, with 20 years of experience as a finance executive working in various senior positions at Fortune 500 companies and early-stage ventures in the biotechnology, software, and network security sectors.

Originally posted here:
Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce the Appointment of Narayan Prabhu as Chief Financial Officer

Global News Feed Comments Off on Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce the Appointment of Narayan Prabhu as Chief Financial Officer | November 5th, 2020

Total revenues increase by 213% on record high quarterly product sales Total revenues increase by 213% on record high quarterly product sales

Read the rest here:
T2 Biosystems Announces Third Quarter 2020 Financial Results

Global News Feed Comments Off on T2 Biosystems Announces Third Quarter 2020 Financial Results | November 5th, 2020

WESTLAKE VILLAGE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that Terrie Curran has been appointed to the Arcutis Board of Directors effective Nov. 2, 2020, and that Alexander Asam, Ph.D. has decided to step down from the Board.

Follow this link:
Arcutis Announces Appointment of Terrie Curran to Board of Directors

Global News Feed Comments Off on Arcutis Announces Appointment of Terrie Curran to Board of Directors | November 5th, 2020

Heidelberg, Germany, November 4, 2020 – Affimed N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced today that two abstracts highlighting data related to the company’s lead innate cell engager (ICE®), AFM13, have been accepted for poster presentation at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held  December 5-8, 2020.

More:
Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition

Global News Feed Comments Off on Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition | November 5th, 2020

Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET

Read the original here:
Trevi Therapeutics to Report Q3 2020 Financial Results on November 11

Global News Feed Comments Off on Trevi Therapeutics to Report Q3 2020 Financial Results on November 11 | November 5th, 2020

Conference call and webcast today at 4:30 p.m. ET

Read the original:
Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Global News Feed Comments Off on Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update | November 5th, 2020

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results for the third quarter ended September 30, 2020, and recent corporate highlights.

Excerpt from:
Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

Global News Feed Comments Off on Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights | November 5th, 2020

WARREN, N.J., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent developments in its business.

View original post here:
Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Global News Feed Comments Off on Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update | November 5th, 2020

-- Interim data from Phase 2 study showed that once-weekly formulation of setmelanotide achieved safety and efficacy results comparable to daily-dosing formulation ---- Additional data from long-term extension study in POMC deficiency obesity showed durable weight loss and reductions in hunger at up to three years on therapy ---- Setmelanotide was generally well tolerated --BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced new clinical data for setmelanotide, its investigational melanocortin-4 receptor (MC4R) agonist, being presented at The Obesity Society’s ObesityWeek® 2020, held virtually from November 2-6, 2020.

See the rest here:
Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020

Global News Feed Comments Off on Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020 | November 5th, 2020

PALO ALTO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 1, 2020, the compensation committee of BridgeBio’s board of directors granted three new employees restricted stock units for an aggregate of 9,566 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

Read more:
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Global News Feed Comments Off on BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | November 5th, 2020

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020. Jeff had previously been appointed as interim CEO in May 2020 while continuing to serve on the Board of Directors.

Link:
BioDelivery Sciences Announces Appointment of Jeff Bailey as Permanent CEO

Global News Feed Comments Off on BioDelivery Sciences Announces Appointment of Jeff Bailey as Permanent CEO | November 5th, 2020

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2020 financial results.

More:
Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update

Global News Feed Comments Off on Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update | November 5th, 2020

PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.

Visit link:
10x Genomics to Participate in the Stifel 2020 Healthcare Conference

Global News Feed Comments Off on 10x Genomics to Participate in the Stifel 2020 Healthcare Conference | November 5th, 2020